抗白念珠菌感染的疫苗及抗体研究进展

白念珠菌是与人类共生的条件致病真菌,能引起免疫力低下患者皮肤黏膜和全身系统性持续感染.系统性念珠菌病是引起免疫力低下患者死亡的主要原因之一.由于临床缺乏念珠菌病的早期诊疗手段、可用的抗真菌药物种类有限且毒副作用大、耐药菌株越来越普遍、新药研发难度大等因素,抗真菌治疗依然面临着严峻挑战.目前有较多研究者致力于阐明白念珠菌感染的宿主免疫应答机制,并试图研发抗白念珠菌感染的免疫治疗方法,使免疫治疗有望成为预防和治疗真菌感染的有效手段.该文将几种抗白念珠菌感染的疫苗和抗体研究进展作简要概述,旨在为新型抗白念珠菌感染疫苗及抗体的研究提供参考.

Progress on vaccine and antibodies against Candida albicans infections

Candida albicans is a commensal opportunistic fungal pathogen in human that causes superficial as well as life-threatening systemic infections in immunocompromised patients.Since the lack of diagnosis methods of candidiasis in early stage,in addition to the narrow range and significant toxicity of available antifungal agents,and the research and development of new drugs are rather difficult,the systemic candidiasis becomes the main causes resulting in death in immunocompromised patients.Therefore,antifungal treatment is still faced with severe challenges.Recently,most research has been devoted to clarify the host immune response mechanisms against C.albicans infections and try to develop the immunotherapy for C.albicans infections; so the vaccine and antibody are expected to be the effective way for prevention and treatment of fungal infections.In this article,progress in research in vaccine and antibody against C.albicans is reviewed,so as to provide a reference for the study of novel vaccine and antibody against C.albicans infections.